Atorvastatin Calcium

WILMINGTON, N.C., Dec. 18, 2025 /PRNewswire/ -- CardioPharma, Inc. (the "Company"), a specialty pharmaceutical company focused on combinatorial drug development for cardiovascular diseases, is seeking applications for secondary analyses of existing datasets to investigate the non-cardiovascular (non-CVD) benefits of the CVD polypill (3 or more medications). While the polypill (fixed-dose combination therapy) is primarily intended for CVD prevention and treatment, emerging evidence suggests potential broader health benefits. This funding opportunity invites investigators to explore these effects, determine how much is mediated by CVD improvements versus direct benefits, and evaluate outcomes in both primary and secondary prevention settings. Dr. Frank Snyder, Chief Medical Officer, stated, "the medical literature has researched and published extensively on the myriad benefits of cardiovascular polypills for years," continuing, "the primary benefits of adherence, safety and efficacy are well known – we want to push our understanding beyond that." Professor of Cardiovascular Medicine at Wake Forest University School of Medicine and CardioPharma Scientific Advisory Board member, Dr. Elsayed Soliman, notes, "Our interest is piqued by the broader potential benefits beyond traditional cardiovascular disease - extending to Alzheimer's disease and related dementias, cognitive decline, cerebral vascular disease including stroke, peripheral vascular disease, chronic kidney disease as well as, potentially, certain ophthalmologic conditions." "By formally commissioning research into these potential non-cardiovascular benefits, CardioPharma is seeking to expand the understanding of how combinatorial cardiovascular medications may benefit less traditional disease states," according to CFO Roy Stimits, "which could benefit an entire new group of patients." CardioPharma's Dr. Daniel Gregory continued, "the global need for these inexpensive medications delivered in a convenient and cost-effective polypill is great. Despite the limited availability in much of the world, this research may help expand patient access by demonstrating even greater need." CardioPharma is dedicated to bringing innovative cardiovascular fixed-dose combinations to markets around the world. Investigators are invited to apply starting February 15, 2026. Further information is available at: CardioPharma Pipeline CardioPharma's pipeline products contain some of the world's most consumed, individually dispensed medications for the prevention and treatment of cardiovascular disease. The lead product, CardiaPill® is a unique formulation combining a cholesterol modifying agent ("statin"), an Angiotensin-converting-enzyme inhibitor (ACE Inhibitor) and anti-platelet agent. Statins moderate cholesterol levels and include products such as Lipitor®, Zocor®, Pravachol®; and Crestor®. ACE inhibitors reduce blood pressure and include products such as Altace®, Lotensin®, Capoten® and Accupril®. Pipeline products also include combinations using Angiotensin II Receptor Blockers (ARBs) as well as different statins and other anti-platelet agents. Simplicity of dosing, improved adherence and significant cost benefits for patients, providers and payors around the world are among the many compelling and well-documented benefits that make these inexpensive products so anticipated. About CardioPharma CardioPharma, Inc. is a specialty pharmaceutical company focused on patent-protected combinatorial cardiovascular medications. CardioPharma's goal is to create drugs that make it easier and more cost-effective for physicians and their patients to reduce the morbidity and mortality of the world's number one killer – cardiovascular disease. The products are unique to the global pharmaceutical industry – highly cost-effective with proven efficacy; providing both patient and provider convenience; promoting adherence, while delivering superior clinical outcomes and economic benefits to all stakeholders. For more information, visit cardiopharma.com or contact Dr. Daniel Gregory [email protected] Forward looking statements The information in this press release contains forward-looking statements including the prospective development, commercialization and regulatory approval in the U.S. and international markets. Words such as "expects," "plans," "believe," "may," "will," "anticipated," "intended" and variations of these words or similar expressions are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors including the Company's ability to raise sufficient funds to bring new products to the global market. SOURCE CardioPharma, Inc. 21% more press release views with Request a Demo

Benefiting over 1.5 million cardiovascular patients, prescription discount cards help reduce a key financial barrier potentially preventing thousands of heart attacks and strokes annuallyESTERO, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Visory Health, a patient-first health tech prescription platform that is transforming the way Veterans, families, and caregivers access affordable healthcare through its prescription discount card, today announced that its solutions have saved Americans nearly $790 million on cardiovascular medications, benefiting over 1.5 million unique patients nationwide since their launch in March 2022. This significant financial relief directly addresses a major obstacle to receiving treatment, helping more individuals afford life-saving prescriptions for conditions like high cholesterol, a key factor in preventing heart attacks and strokes. According to recent research published in the Journal of General Internal Medicine, increasing access to cholesterol-lowering therapy could deliver a substantial impact on overall public health. The simulation study predicted that if all eligible U.S. adults received guideline-directed treatment for high cholesterol, it could annually prevent: More than 39,000 deaths from heart attacksNearly 100,000 non-fatal heart attacksUp to 65,000 strokes In addition to saving the lives of many, the study states that resolving the “widespread underuse” of these crucial medications could lead to an estimated $25.3 billion reduction in annual healthcare expenditures. By reducing the cost of essential medications for heart health, patients are better equipped to adhere to their treatment plans, which can significantly lower their risk of devastating cardiovascular events. "Heart disease has held the title as the leading cause of death for decades, so it’s essential to bring awareness to solutions that break down the barriers that prevent people from accessing affordable medications,” said Visory Health Chief Pharmacy Officer Rebecca Irvin, Pharm.D. "We’re dedicated to continuing our work towards a future where financial considerations do not prevent Americans from accessing the medications they need to live healthier, longer lives.” Savings on commonly prescribed statins, such as atorvastatin (generic for Lipitor), rosuvastatin (generic for Crestor) and simvastatin (generic for Zocor), are consistently available through Visory Health’s prescription discount card, ensuring patients can access them without financial strain. Using Visory Health's free prescription discount card, patients can compare medication costs at over 37,000 pharmacies nationwide, including Kroger, Stop & Shop, Publix, Walgreens and more. This gives patients a clearer view of prices and more options for affordable treatment when using insurance is not possible or cost-effective. "When you understand the weight families carry in managing chronic health conditions, it becomes clear that the status quo isn’t good enough,” said Alexandra Robertson, Senior Vice President of Growth at Visory Health. “Achieving true health equity means not just innovating technology but also thoughtfully improving the systems that shape access for so many.” With Visory Health, patients can receive up to 80% off their medication costs by downloading the Visory Health app in the App Store or Google Play Store and adding the digital prescription card to Apple Wallet or Google Wallet. For those without access to a digital wallet, the card is also available for download on the “Rx Savings Card” page on Visory Health’s website. About Visory Health Visory Health is a patient-first health tech platform transforming how everyone, including Veterans, families, caregivers and underserved individuals, has access to healthcare. Visory Health’s model puts customers’ needs at the core of how it operates. They have saved millions of customers' money on prescription medications, creating healthier families and communities. With a network of over 37,000 pharmacy partners nationwide, including Walgreens, Kroger, Publix, Stop & Shop, and more, Visory Health delivers affordable prescription prices nationwide and is free to use. To learn more, visit www.visoryhealth.com. Media Contact Erica Torres Uproar by Moburst for Visory Health erica.torres@moburst.com